Sequenom shares jump on Down syndrome test demand; Arno Therapeutics develops companion diagnostic;

> Sequenom ($SQNM) shares jumped on increased demand for its MaterniT21 prenatal blood test for trisomy 21 (Down syndrome). Article

> According to results presented at the annual meeting of the American College of Rheumatology, increased levels of the biomarker BLyS (B-lymphocyte stimulator) predict flares in people with systemic lupus erythematosus. Article

> Arno Therapeutics is developing a clinical biomarker program for a companion diagnostic for its investigational anti-cancer drug onapristone. Cancer cells that express the activated form of the progesterone receptor (APR) are more likely to respond to the drug. Press release

> The biomarker ST2, pinpointed by Critical Diagnostics' Presage ST2 assay, predicts the risk of heart failure and mortality in HIV-positive people and in the general population. Press release | Press release

> Genes predispose some Asian nonsmoking women to lung cancer. Press release

> Microvesicles, tiny cell particles dropped off by cancer cells, could be used as blood biomarkers to diagnose cancer. Article

> Metabolic signatures in glioma, a type of tumor that starts in the brain, may lead to personalized therapy. Press release | Abstract

> The Drugs for Neglected Diseases initiative (DNDi) has received a $3 million Strategic Translation Award from the Wellcome Trust to identify new biomarkers for the evaluation of treatment efficacy in Chagas disease, a potentially fatal neglected tropical disease. Press release

> Diazyme has FDA clearance to market its Cystatin C POC Test Kit for early testing of kidney disease on its SMART Point of Care System. Press release

> Telomere length marks mortality. Press release

And Finally… Man tries a pregnancy test as a joke and it comes back positive; Reddit users may have saved his life by telling him to get checked out for testicular cancer. Article

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.